ACM
ACRS icon

ADAR1 Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

ADAR1 Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-132,426
Closed -$497K – 280
2026
Q1 		$497K Sell
132,426
-481,560
-78% -$1.62M 0.03% 202
2025
Q4 		$1.85M Buy
613,986
+240,304
+64% +$607K 0.14% 104
2025
Q3 		$710K Buy
+373,682
New +$651K 0.07% 115
2024
Q4 		– Sell
-90,000
Closed -$104K – 217
2024
Q3 		$104K Buy
+90,000
New +$110K 0.02% 186

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

ADAR1 Capital Management's ACRS Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 132,426 shares — an estimated $497K sold.

ADAR1 Capital Management first reported a position in ACRS in Q3 2024 and held it in 4 quarters. The position peaked at $1.85M in Q4 2025. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 132,426 Aclaris Therapeutics shares in Q2 2026, an estimated $497K.
  • ADAR1 Capital Management first reported a position in Aclaris Therapeutics in Q3 2024 and held it in 4 quarters.
  • ADAR1 Capital Management's Aclaris Therapeutics position peaked at $1.85M in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.